First patient dosed in Phase 3 trial of bemdaneprocel for Parkinson’s
The first patient has been dosed in exPDite-2, a registrational Phase 3 clinical trial testing the safety and efficacy of bemdaneprocel, an investigational stem cell therapy that Bluerock Therapeutics is developing for Parkinson’s disease. The trial (NCT06944522), originally scheduled to begin earlier this year, is recruiting…